Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee - Report - MDSpire
Advertisement
Defining lines of therapy in haematological malignancies: a proposed systematic and comprehensive framework from the EBMT Practice Harmonisation and Guidelines Committee
Clinical Report: Establishing a Comprehensive Framework for Therapy Lines in Hematological Malignancies
Overview
The EBMT Practice Harmonisation and Guidelines Committee has developed a standardized framework for defining lines of therapy (LoT) in hematological malignancies. This initiative aims to enhance clarity in treatment reporting and support evidence-based decision-making.
Background
The management of hematological malignancies has evolved significantly with the introduction of targeted therapies and immunotherapies. However, variability in defining lines of therapy complicates clinical practice and research. A standardized definition is crucial to improve data harmonization and treatment reporting.
Data Highlights
No numerical data provided in the source material.
Key Findings
A line of therapy (LoT) is defined as a coherent therapeutic episode aimed at achieving or maintaining disease control.
A new LoT is assigned at documented progression, relapse, or primary refractory disease.
Bridging therapies prior to cellular therapy are considered part of the same LoT as the definitive treatment.
Variability in LoT definitions can hinder clinical care and research.
The EBMT aims to harmonize data collection and improve clarity in treatment reporting.
Clinical Implications
Standardizing the definition of LoT is essential for improving clinical practice and research outcomes in hematological malignancies. This framework will facilitate better communication among healthcare providers and enhance the quality of data collected in clinical settings.
Conclusion
The establishment of a comprehensive framework for therapy lines in hematological malignancies is a critical step towards improving treatment consistency and supporting evidence-based practices.
by Alessandro Criscimanna, Jacques-Emanuel Galimard, Isabel Sánchez-Ortega, Patrick J. Hayden, Laurent Garderet, Anna Sureda, Fabio Ciceri, Donal P. McLornan, Krzysztof Kałwak, Antonio M. Risitano, Francesco Onida, Ibrahim Yakoub-Agha, Ali Bazarbachi, Annalisa Ruggeri
